Navamedic ASA launches Eroxon® in Denmark

Publisert: 05.05.2025

Navamedic ASA: Annual Report 2024

Publisert: 30.04.2025

Navamedic Q1 2025: Strong start of the year and well-positioned for future growth

Publisert: 30.04.2025

Navamedic ASA: Imdur® distribution agreement extended to 2032

Publisert: 29.04.2025

Navamedic ASA: Invitation to 2025 1st quarter presentation

Publisert: 28.04.2025

Navamedic Welcomes CHMP’s Positive Review of Mysimba’s Cardiovascular Safety

Publisert: 02.04.2025